Dual inhibition of STAT3 and STAT5 may overcome imatinib resistance in chronic myeloid leukemia

Dual inhibition of STAT3 and STAT5 may overcome imatinib resistance in chronic myeloid leukemia

ABSTRACTBackground: Clinical outcome of patients with chronic myeloid leukemia (CML) has improved dramatically since the introduction of tyrosine kinase inhibitors such as imatinib mesylate (IM). However, approximately 20-30% of patients experience IM resistance. SH-4-54, which targets the SH2 domai...

Full description

Bibliographic Details
Main Authors: Lingling Yin, Jiawen Xu, Wenjian Wu, Mingshan Niu, Zhenyu Li, Feng Zhu, Kailin Xu
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Hematology
Subjects:
Chronic myeloid leukemia
resistance
STAT3/5 inhibitor
SH-4-54
therapeutic targeting
Online Access:https://www.tandfonline.com/doi/10.1080/16078454.2023.2224625

Similar Items

Similar Items